FINWIRES · TerminalLIVE
FINWIRES

Halozyme Therapeutics Q2 Adjusted Earnings, Revenue Rise; Shares Gain After Hours

By

Halozyme Therapeutics (HALO) reported Q2 non-GAAP earnings late Thursday of $2.28 per diluted share, up from $1.54 a year earlier.

Analysts polled by FactSet expected $1.79.

Revenue in the three months ended June 30 rose to $481 million from $325.7 million a year earlier.

Analysts projected $402.3 million.

The company increased full-year guidance to adjusted EPS of $8.65 to $9 on revenue of $1.835 billion to $1.91 billion. The prior outlook was EPS of $7.75 to $8.25 on revenue of $1.71 billion to $1.81 billion.

Analysts project EPS $7.94 on revenue of $1.77 billion.

Halozyme shares rose 4.9% in after-hours trading.

Related Articles

Wire

Cirrus Logic Fiscal Q1 Adjusted Earnings, Revenue Rise

Cirrus Logic (CRUS) reported fiscal Q1 adjusted earnings late Wednesday of $1.84 per diluted share, up from $1.51 a year earlier.Analysts polled by FactSet expected $1.81.Revenue in the three months ended June 27 rose to $459.7 million from $407.3 million a year ago.Four analysts expected $460.3 million.The company expects fiscal Q2 revenue of $510 million to $570 million. Analysts project $570.1 million.Cirrus Logic shares fell 3.4% in after-hours trading.

$CRUS
Wire

Tenaris Q2 Earnings, Revenue Fall

Tenaris (TS) reported Q2 earnings late Wednesday of $0.95 per American depository share, down from $0.99 a year earlier.Four analysts polled by FactSet expected $0.83.Revenue in the three months ended June 30 fell to $2.97 billion from $3.09 billion a year earlier.Analysts expected $2.93 billion.Tenaris shares fell 5.5% in after-hours trading.

$TS
Wire

Block Q2 Adjusted Earnings, Revenue Rise

Block (XYZ) reported Q2 adjusted earnings late Wednesday of $1.02 per diluted share, up from $0.62 a year earlier.Analysts polled by FactSet expected $0.87.Revenue in the three months ended June 30 rose to $6.62 billion from $6.05 billion a year earlier.Analysts projected $6.47 billion.Block expects Q3 adjusted diluted EPS of $1.02. Analysts project $1.01.The company increased full-year adjusted EPS guidance to $4.02 from the prior outlook of $3.85. Analysts project $3.90.Block shares fell 1.7% in after-hours trading.

$XYZ
Halozyme Therapeutics Q2 Adjusted Earnings, Revenue Rise; Shares Gain After Hours | FINWIRES